Alivus Life Sciences Limited (BOM:543322)

Market Cap	123.22B
Revenue (ttm)	23.87B
Net Income (ttm)	4.86B
Shares Out	n/a
EPS (ttm)	39.52
PE Ratio	25.37
Forward PE	22.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,251
Average Volume	4,437
Open	988.20
Previous Close	1,002.35
Day's Range	988.20 - 1,005.55
52-Week Range	820.05 - 1,335.00
Beta	n/a
RSI	37.97
Earnings Date	Jul 23, 2025

About Alivus Life Sciences

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, in...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2011
• Employees: 2,014
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543322

Financial Performance

In 2024, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.